Safeline’s Italian partner, Chiesi Farmaceutici, focuses their attention on the treatment and care of patients suffering from diseases treated primarily by specialists in the hospital setting, which are potentially life-threatening. The commitment in this area is considered strategic for the Group’s future and the potential for significant social impact.

We offer the medical and scientific communities’ new therapeutic options to treat severe heterogeneous conditions: Cystic Fibrosis, Solid Organ Transplantation, Inflammatory Bowel Diseases.


The term rare applies to those diseases affecting a limited number of people with a prevalence below a given cut-off point, which is codified by each country’s legislation. The EU sets this threshold at 0.0005% of the population, i.e., when it affects less than 1 in 2000 inhabitants. A disease or disorder is defined as rare in the USA when it affects fewer than 200,000 Americans at any given time. There may be as many as 7,000 rare diseases.

Rare diseases are characterised by a broad diversity of disorders and symptoms that vary from disease to disease and from patient-to-patient suffering from the same condition.

Relatively common symptoms can hide underlying rare diseases leading to misdiagnosis and delaying treatment, and they are often chronic, progressive, degenerative, and frequently life-threatening.

The lack of scientific knowledge and quality information on these diseases often results in a delay in diagnosis. Moreover, it is equally difficult for patients to access effective treatment and receive social and medical care for the condition. This often results in heavy social and financial burdens on patients.

This explains why we focus mainly on treatment and assistance for rare disease sufferers; our commitment concentrates on this field. We believe this therapeutic area is of great importance and social impact.